InterCure Announces Strong First Half 2025 Results Amid Strategic Expansion
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Intercure ( (IL:INCR) ) has provided an update.
InterCure Ltd. reported its financial results for the first half of 2025, highlighting NIS 130 million in revenue and NIS 12 million in positive operating cash flow, marking its eleventh consecutive half of positive Adjusted EBITDA. Despite challenges such as the October 7 attack and ongoing war in Gaza, the company resumed production and launched over 40 new SKUs. InterCure is strategically expanding its international presence, notably through the acquisition of Botanico Ltd. (ISHI), which enhances its access to premium U.S. genetics and cultivation technologies. The company is also monitoring U.S. regulatory changes, positioning itself to capitalize on potential cannabis rescheduling.
The most recent analyst rating on (IL:INCR) stock is a Hold with a ILs548.00 price target. To see the full list of analyst forecasts on Intercure stock, see the IL:INCR Stock Forecast page.
More about Intercure
InterCure Ltd., operating under the brand Canndoc, is a leading and profitable cannabis company outside North America. It is Israel’s largest licensed cannabis producer, offering GMP-certified and pharmaceutical-grade medical cannabis products. The company utilizes a vertically integrated ‘seed-to-sale’ model and has a strong distribution network and international partnerships, positioning it as a leader in the global cannabis market.
Average Trading Volume: 61,653
Technical Sentiment Signal: Sell
Current Market Cap: ILs291.5M
See more insights into INCR stock on TipRanks’ Stock Analysis page.
